TSE:CPH Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis C$14.51 -0.05 (-0.34%) As of 09/16/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and Trends About Cipher Pharmaceuticals Stock (TSE:CPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cipher Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$14.31▼C$14.7650-Day RangeC$13.68▼C$17.9552-Week RangeC$12.48▼C$20.56Volume17,927 shsAverage Volume30,706 shsMarket CapitalizationC$368.77 millionP/E Ratio12.96Dividend YieldN/APrice TargetC$17.00Consensus RatingHold Company Overview Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. Read More Cipher Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreCPH MarketRank™: Cipher Pharmaceuticals scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingHold Consensus RatingCipher Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Upside PotentialCipher Pharmaceuticals has a consensus price target of C$17.00, representing about 17.2% upside from its current price of C$14.51.Amount of Analyst CoverageCipher Pharmaceuticals has received no research coverage in the past 90 days.Read more about Cipher Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cipher Pharmaceuticals is 12.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Cipher Pharmaceuticals is 12.96, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.86.Price to Book Value per Share RatioCipher Pharmaceuticals has a P/B Ratio of 2.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CPH. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCipher Pharmaceuticals does not currently pay a dividend.Dividend GrowthCipher Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentCipher Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cipher Pharmaceuticals this week, compared to 0 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cipher Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders42.00% of the stock of Cipher Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.26% of the stock of Cipher Pharmaceuticals is held by institutions.Read more about Cipher Pharmaceuticals' insider trading history. Receive CPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPH Stock News HeadlinesCipher Pharmaceuticals (TSE:CPH) Shares Pass Below 50-Day Moving Average - Time to Sell?September 15 at 3:23 AM | americanbankingnews.comCipher Pharmaceuticals' Ownership Of Certain Abscoria-Related Clinical Data Affirmed by US CourtSeptember 2, 2026 | marketscreener.comMHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 17 at 1:00 AM | Stansberry Research (Ad)Cipher Pharmaceuticals Secures Court Confirmation Of Arbitration AwardSeptember 2, 2026 | rttnews.comCipher Pharmaceuticals Schedules Q2 2026 Earnings Release and Conference CallJuly 31, 2026 | finance.yahoo.comCipher Pharmaceuticals Announces Results of Annual General Meeting of ShareholdersJune 18, 2026 | finance.yahoo.comWhy The Cipher Pharmaceuticals (TSX:CPH) Story Is Shifting As Analysts Lift Valuation TargetsMay 23, 2026 | finance.yahoo.comResults: Cipher Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New ForecastsMay 11, 2026 | finance.yahoo.comSee More Headlines CPH Stock Analysis - Frequently Asked Questions How have CPH shares performed this year? Cipher Pharmaceuticals' stock was trading at C$15.06 on January 1st, 2026. Since then, CPH shares have decreased by 3.7% and is now trading at C$14.51. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (TSE:CPH) released its earnings results on Tuesday, August, 11th. The company reported $0.21 earnings per share (EPS) for the quarter. The company had revenue of $17.14 million for the quarter. Cipher Pharmaceuticals had a trailing twelve-month return on equity of 22.74% and a net margin of 58.81%. Read the conference call transcript. How do I buy shares of Cipher Pharmaceuticals? Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Cipher Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Enbridge (ENB), Bellatrix Exploration (BXE), Crescent Point Energy (CPG), Manulife Financial (MFC), Surge Energy (SGY) and Toronto-Dominion Bank (TD). Company Calendar Last Earnings8/11/2026Today9/17/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolTSE:CPH Previous SymbolTSE:DND CIKN/A Webwww.cipherpharma.com Phone+1-905-6025840FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for Cipher PharmaceuticalsC$17.00 High Price TargetC$17.00 Low Price TargetC$17.00 Potential Upside/Downside+17.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)C$1.12 Trailing P/E Ratio12.96 Forward P/E Ratio11.24 P/E GrowthN/ANet IncomeC$11.41 million Net Margins58.81% Pretax MarginN/A Return on Equity22.74% Return on Assets7.90% Debt Debt-to-Equity Ratio0.27 Current Ratio1.59 Quick Ratio2.67 Sales & Book Value Annual SalesC$49.62 million Price / Sales7.43 Cash FlowC$4.11 per share Price / Cash Flow3.53 Book ValueC$5.40 per share Price / Book2.69Miscellaneous Outstanding Shares25,415,000Free FloatN/AMarket CapC$368.77 million OptionableNot Optionable Beta1.05 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (TSE:CPH) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThe IRA Mistake That Could Cost Americans 55+ Thousands in 2026JPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...Golden Crest Metals | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cipher Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
